MX383293B - Metodos de preparacion de polinucleotidos usando composiciones salinas de cationes multivalentes. - Google Patents

Metodos de preparacion de polinucleotidos usando composiciones salinas de cationes multivalentes.

Info

Publication number
MX383293B
MX383293B MX2017011642A MX2017011642A MX383293B MX 383293 B MX383293 B MX 383293B MX 2017011642 A MX2017011642 A MX 2017011642A MX 2017011642 A MX2017011642 A MX 2017011642A MX 383293 B MX383293 B MX 383293B
Authority
MX
Mexico
Prior art keywords
polynucleotide
salt
multivalent cation
preparation
polynucleotides
Prior art date
Application number
MX2017011642A
Other languages
English (en)
Spanish (es)
Other versions
MX2017011642A (es
Inventor
Premchandran H Ramiya
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of MX2017011642A publication Critical patent/MX2017011642A/es
Publication of MX383293B publication Critical patent/MX383293B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/113Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/314Phosphoramidates
    • C12N2310/3145Phosphoramidates with the nitrogen in 3' or 5'-position
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3515Lipophilic moiety, e.g. cholesterol
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • C12P19/30Nucleotides
    • C12P19/34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07Nucleotidyltransferases (2.7.7)
    • C12Y207/07049RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017011642A 2015-04-23 2016-04-21 Metodos de preparacion de polinucleotidos usando composiciones salinas de cationes multivalentes. MX383293B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562151891P 2015-04-23 2015-04-23
PCT/US2016/028657 WO2016172346A1 (en) 2015-04-23 2016-04-21 Methods of polynucleotide preparation using multivalent cation salt compositions

Publications (2)

Publication Number Publication Date
MX2017011642A MX2017011642A (es) 2017-11-02
MX383293B true MX383293B (es) 2025-03-13

Family

ID=55911083

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011642A MX383293B (es) 2015-04-23 2016-04-21 Metodos de preparacion de polinucleotidos usando composiciones salinas de cationes multivalentes.

Country Status (36)

Country Link
US (2) US10745687B2 (https=)
EP (1) EP3286203B1 (https=)
JP (4) JP2018513127A (https=)
KR (1) KR102401252B1 (https=)
CN (2) CN107429247B (https=)
AU (2) AU2016250576C1 (https=)
BR (1) BR112017019627B1 (https=)
CA (1) CA2978191C (https=)
CL (1) CL2017002314A1 (https=)
CO (1) CO2017009217A2 (https=)
CY (1) CY1123197T1 (https=)
DK (1) DK3286203T3 (https=)
EA (1) EA035885B1 (https=)
ES (1) ES2798270T3 (https=)
HR (1) HRP20201218T1 (https=)
HU (1) HUE051148T2 (https=)
IL (1) IL254222A0 (https=)
LT (1) LT3286203T (https=)
MA (2) MA42157A (https=)
MD (1) MD3286203T2 (https=)
ME (1) ME03811B (https=)
MX (1) MX383293B (https=)
MY (1) MY187804A (https=)
PE (2) PE20221275A1 (https=)
PH (1) PH12017501927B1 (https=)
PT (1) PT3286203T (https=)
RS (1) RS60645B1 (https=)
SA (1) SA517390103B1 (https=)
SG (2) SG11201707893RA (https=)
SI (1) SI3286203T1 (https=)
SM (1) SMT202000389T1 (https=)
TN (1) TN2017000411A1 (https=)
TW (1) TWI736532B (https=)
UA (1) UA124521C2 (https=)
WO (1) WO2016172346A1 (https=)
ZA (1) ZA201706041B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42157A (fr) 2015-04-23 2018-02-28 Geron Corp Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent
AU2016341309A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Cancer vaccines
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
EP3554556B1 (en) 2016-12-19 2022-03-09 Ventana Medical Systems, Inc. Peptide nucleic acid conjugates
MA49914A (fr) * 2017-08-18 2021-04-21 Modernatx Inc Procédés analytiques par hplc
JP7441455B2 (ja) * 2017-09-22 2024-03-01 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト 筋ジストロフィーの処置のためのチオモルホリノオリゴヌクレオチド
JP7727385B2 (ja) * 2017-12-18 2025-08-21 ヴェンタナ メディカル システムズ, インク. ペプチド核酸コンジュゲート

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046720A (en) 1974-01-17 1977-09-06 California Institute Of Technology Crosslinked, porous, polyacrylate beads
US4413070A (en) 1981-03-30 1983-11-01 California Institute Of Technology Polyacrolein microspheres
US4678814A (en) 1981-03-30 1987-07-07 California Institute Of Technology Polyacrolein microspheres
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
DE69120821T2 (de) 1990-08-31 1997-01-23 The Regents Of The University Of Minnesota, Minneapolis, Minn. Polyethylenglykol-Derivate für Festphasenanwendungen
US5281701A (en) 1991-07-12 1994-01-25 Applied Biosystems, Inc. Process and compounds for RNA synthesis
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
CZ274596A3 (en) 1994-03-18 1997-03-12 Lynx Therapeutics Oligonucleotide n3 - p5 phosphoramidates and process of their synthesis and hybridization
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
CA2274586A1 (en) 1996-12-20 1998-07-02 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
US5998604A (en) 1997-09-15 1999-12-07 The Perkin-Elmer Corporation Polynucleotide purification method
US6114519A (en) 1997-10-15 2000-09-05 Isis Pharmaceuticals, Inc. Synthesis of sulfurized oligonucleotides
US6465628B1 (en) 1999-02-04 2002-10-15 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
CN1317291C (zh) 1999-09-10 2007-05-23 杰龙公司 寡核苷酸n3′→p5′硫代氨基磷酸酯,其合成及应用
JP2002060341A (ja) 2000-08-21 2002-02-26 Terumo Corp 止血剤
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
CA2440322C (en) 2001-03-23 2014-09-09 Geron Corporation Oligonucleotide conjugates
PL1667522T3 (pl) * 2003-09-09 2018-06-29 Geron Corporation Zmodyfikowane oligonukleotydy do hamowania telomerazy
US20120329858A1 (en) 2010-08-04 2012-12-27 Geron Corporation Modified oligonucleotides for telomerase inhibition
TW200540180A (en) 2004-05-28 2005-12-16 Sankyo Co Telomerase inhibitor ena oligonucleotide
HRP20171705T1 (hr) 2004-07-02 2017-12-15 Geron Corporation Sinteza zaštićenih 3’-amino-nukleozidnih monomera
US20070212704A1 (en) * 2005-10-03 2007-09-13 Applera Corporation Compositions, methods, and kits for amplifying nucleic acids
JP5732196B2 (ja) * 2006-11-01 2015-06-10 バイオジェン アイデック エムエー インコーポレイティドBiogen Idec Inc. 低pHおよび二価カチオンを用いる生物高分子を単離する方法
BR112013003875B1 (pt) 2010-08-20 2021-10-05 Replicor Inc Composições farmacêuticas compreendendo complexo de quelato de oligonucleotídeo, formulação de oligonucleotídeo, e usos
US9106103B2 (en) 2011-09-23 2015-08-11 Eaton Corporation Unintteruptible power supply systems and methods employing on-demand energy storage
US9006630B2 (en) 2012-01-13 2015-04-14 Altasens, Inc. Quality of optically black reference pixels in CMOS iSoCs
AR091065A1 (es) 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
JP6450308B2 (ja) * 2012-06-14 2019-01-09 ライフ テクノロジーズ コーポレーション ポリメラーゼ連鎖反応(pcr)のための新規の組成物、方法、およびキット
RS59363B1 (sr) * 2012-12-07 2019-11-29 Geron Corp Upotreba inhibitora telomeraze imetelstata za lečenje mijelofibroze
JOP20200257A1 (ar) * 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
MA42157A (fr) 2015-04-23 2018-02-28 Geron Corp Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent

Also Published As

Publication number Publication date
AU2016250576B2 (en) 2021-02-04
SI3286203T1 (sl) 2020-10-30
BR112017019627B1 (pt) 2022-11-29
CN107429247A (zh) 2017-12-01
CA2978191A1 (en) 2016-10-27
BR112017019627A2 (pt) 2018-05-15
JP2021152079A (ja) 2021-09-30
EP3286203B1 (en) 2020-05-06
WO2016172346A1 (en) 2016-10-27
EP3286203A1 (en) 2018-02-28
PH12017501927A1 (en) 2018-03-05
CN107429247B (zh) 2021-08-13
AU2016250576C1 (en) 2021-05-06
US20200339975A1 (en) 2020-10-29
MD3286203T2 (ro) 2020-08-31
ZA201706041B (en) 2020-11-25
LT3286203T (lt) 2020-07-27
PE20171785A1 (es) 2017-12-27
JP2018513127A (ja) 2018-05-24
SMT202000389T1 (it) 2020-09-10
DK3286203T3 (da) 2020-06-02
CO2017009217A2 (es) 2018-02-20
CY1123197T1 (el) 2021-10-29
US20160312227A1 (en) 2016-10-27
MA42157A (fr) 2018-02-28
PH12017501927B1 (en) 2022-09-02
TW201706284A (zh) 2017-02-16
US11441144B2 (en) 2022-09-13
JP2025061848A (ja) 2025-04-11
CL2017002314A1 (es) 2018-05-04
PT3286203T (pt) 2020-07-08
CN113564168B (zh) 2024-10-25
ME03811B (me) 2021-04-20
HUE051148T2 (hu) 2021-03-01
KR102401252B1 (ko) 2022-05-24
SA517390103B1 (ar) 2021-07-14
KR20170138399A (ko) 2017-12-15
CA2978191C (en) 2022-10-04
JP2022168017A (ja) 2022-11-04
TWI736532B (zh) 2021-08-21
CN113564168A (zh) 2021-10-29
NZ735042A (en) 2021-11-26
PE20221275A1 (es) 2022-09-01
AU2021202803A1 (en) 2021-06-03
TN2017000411A1 (en) 2019-01-16
HRP20201218T1 (hr) 2020-12-11
US10745687B2 (en) 2020-08-18
ES2798270T3 (es) 2020-12-10
SG11201707893RA (en) 2017-11-29
AU2016250576A1 (en) 2017-09-21
MY187804A (en) 2021-10-26
IL254222A0 (en) 2017-10-31
EA035885B1 (ru) 2020-08-27
EA201791753A1 (ru) 2018-04-30
SG10201909816PA (en) 2019-11-28
UA124521C2 (uk) 2021-10-05
RS60645B1 (sr) 2020-09-30
HK1251234A1 (en) 2019-01-25
MX2017011642A (es) 2017-11-02
MA42569B1 (fr) 2020-08-31

Similar Documents

Publication Publication Date Title
MX383293B (es) Metodos de preparacion de polinucleotidos usando composiciones salinas de cationes multivalentes.
JOP20200213B1 (ar) جزيئات رابطة لـ pd-1 وطرق استخدامها
CL2018003136A1 (es) Proteínas de unión específica y usos de las mismas.
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
EA201992696A2 (ru) Составы собирателей и способы их применения
BR112017003582A2 (pt) anticorpos, composições e usos
BR112018010410A8 (pt) método para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1
BR112016030908A2 (pt) moléculas com especificidade para cd45 e cd79
MX2023000738A (es) Proteinas de union a antigeno que activan el receptor de leptina.
BR112018005573A2 (pt) ?polipeptídeos de ligação a cd3?
BR112014007852A2 (pt) nucleosídeos, nucleotídeos e ácidos nucleicos modificados e usos dos mesmos
BR112014009066B8 (pt) molécula de ácido nucleico, método para a sintetização de uma molécula de dna de triciclo-fosforotioato e composição farmacêutica
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
EA201690492A1 (ru) Проникающие в клетку конъюгаты и способы их применения
WO2016100803A3 (en) Methods of treating tissue calcification
BR112018007960A2 (pt) conjugado, proteína pcrv, composição imunogênica, métodos de preparação de uma composição imunogênica, de tratamento e de produção de um bioconjugado, polinucleotídeo, vetor, célula hospedeira, e, bioconjugado.
BR112017025496A2 (pt) Moléculas de ligação neutralizantes anti- influenza e usos das mesmas
BR112016024462A2 (pt) ?métodos para a preparação de uma proteína, proteína heteromultimérica, composição e célula hospedeira?
BR112016025196A2 (pt) composições de oligonucleotídeo e métodos de fazê-las
WO2014145870A3 (en) Novel compositions, methods and kits for blood typing
BR112015017981A2 (pt) anticorpo humano específico para metapneumovírus humano, ou fragmento de ligação de antígeno do mesmo, seu uso e composição farmacêutica o compreendendo, bem como ácido nucleico isolado, vetor de expressão recombinante e célula hospedeira
BR112017025872A2 (pt) proteínas de ligação multiespecíficas
박정선 Interdisciplinary Dance Research Methods for Undergraduate Dance Program
Fleming et al. Looking forward: Preparing Yukon teachers for Yukon schools: Review of the Yukon native teacher education program at Yukon College, 2011-2012
BR112015031194A2 (pt) Molécula quimérica e método para fazer a mesma, polinucleotídeo ou um conjunto de polinucleotídeos, vetor ou um conjunto de vetores, célula hospedeira, composição farmacêutica, uso dos anteriores, e método para aumentar a atividade de fviii da molécula quimérica